利拉鲁肽与司美格鲁肽用于减肥的成本效益分析。
Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis.
机构信息
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Maccabi Healthcare Services, Tel Aviv, Israel.
出版信息
Obesity (Silver Spring). 2023 Jun;31(6):1510-1513. doi: 10.1002/oby.23752.
OBJECTIVE
Higher doses of the glucagon-like peptide-1 agonists liraglutide and, more recently, semaglutide have demonstrated a significant reduction in body weight. However, their comparative value for money for this indication is unclear.
METHODS
The cost needed to treat to achieve a 1% reduction in body weight using semaglutide or liraglutide was calculated. The body weight reductions were extracted from the published STEP 1 trial and the SCALE trial results, respectively. A scenario analysis was performed to mitigate the primary differences between the two studies' populations. Drug costs were based on US GoodRx prices as of October 2022.
RESULTS
Liraglutide in STEP 1 resulted in a weight loss of 5.4% (95% CI: 5%-5.8%). Semaglutide in SCALE resulted in a weight loss of 12.4% (95% CI: 11.5%-13.4%). The total cost of therapy with liraglutide during the trial was estimated at $17,585 compared with $22,878 with semaglutide. Accordingly, the cost needed to treat per 1% of body weight reduction with liraglutide is estimated at $3256 (95% CI: $3032-$3517) compared with $1845 (95% CI: $1707-$1989) with semaglutide.
CONCLUSIONS
Semaglutide provides significantly better value for money than liraglutide for weight reduction.
目的
胰高血糖素样肽-1 激动剂利拉鲁肽和最近的司美格鲁肽的高剂量已证明可显著减轻体重。然而，它们在该适应证下的性价比尚不清楚。
方法
计算使用司美格鲁肽或利拉鲁肽治疗达到体重降低 1%所需的成本。体重减轻数据分别从已发表的 STEP 1 试验和 SCALE 试验结果中提取。进行了情景分析以减轻两项研究人群之间的主要差异。药物成本基于截至 2022 年 10 月的美国 GoodRx 价格。
结果
STEP 1 中的利拉鲁肽导致体重减轻 5.4%（95%CI：5%-5.8%）。SCALE 中的司美格鲁肽导致体重减轻 12.4%（95%CI：11.5%-13.4%）。在试验期间，利拉鲁肽治疗的总费用估计为 17585 美元，而司美格鲁肽为 22878 美元。因此，用利拉鲁肽治疗每降低 1%体重所需的治疗费用估计为 3256 美元（95%CI：3032-3517 美元），而用司美格鲁肽则为 1845 美元（95%CI：1707-1989 美元）。
结论
与利拉鲁肽相比，司美格鲁肽在减重方面具有更高的性价比。
Zotero 插件